Stock Analysis·← Pickers

PACB

Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Inc. (PACB) is currently in a range/mixed trend, above the 50-day MA but below the 200-day MA. RSI is at 50.9, with 1/3 trend checks passing.

Price
$1.53
2026-07-16
Trend score
1/3
Range / Mixed
RSI (14)
50.9
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

PACB with MA50 and MA200

2.672.281.901.511.1207/3110/2401/2204/1707/15
PACB2025-07-312026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$1.44+5.99% vs price
MA200
$1.71-10.48% vs price
RSI (14)
50.9Neutral zone
MACD Signal
MixedMACD near signal line
Macro Support
$1.19–$1.2319.6% below price · 2 touches
Support Quality
2 touches1.1× zone volume
Chart Summary
Trend summary for PACB

Pacific Biosciences of California, Inc. (PACB) currently looks more uncertain than directional, with a fairly mixed technical picture. The latest available price is $1.53, and 1 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 6.0% and below the 200-day moving average by 10.5%.

Momentum and stretch context

PACB currently has an RSI reading of 50.9, which sits in a neutral range. That usually means momentum is not especially stretched in either direction, so traders may need to rely more on chart structure than on oscillator extremes alone.

What traders may watch next

This page is designed to help you quickly understand what the PACB chart looks like before opening the full dashboard. The aim is not to tell you what to buy or sell, but to make it easier to judge whether the stock is trending cleanly, becoming stretched, or simply moving in a more awkward range.

Company profile

About Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.

Sector
Healthcare
Industry
Medical - Devices
CEO
Christian O. Henry
Employees
485
Market cap
$475.2M
Beta
2.29
52-week range
$1.09 – $2.73
Dividend
No
Exchange
NASDAQ
Country
US
IPO date
27 Oct 2010
ISIN
US69404D1081
CUSIP
69404D108
Website
pacb.com
Company profile data from Financial Modeling Prep. PACB listed on NASDAQ.
Share dilution

PACB shares outstanding over time

Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.

Jun 2019Mar 2026
Shares outstanding (latest)
305.8M
Since Jun 2019
+100.2%
Trend
More shares outstanding
Historical shares-outstanding data from Financial Modeling Prep. PACB28 data points from Jun 2019 to Mar 2026.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about PACB

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.